IRMD Iradimed Corp
- Stocks
- Healthcare
- NASDAQ: IRMD
Price (delayed)
$66.17
Market cap
$841.68M
P/E Ratio
40.6
Dividend/share
$0.64
EPS
$1.63
Enterprise value
$788.69M
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system
Highlights
The company's debt has shrunk by 100% QoQ and by 100% YoY
Iradimed's equity has increased by 18% YoY and by 4.7% QoQ
IRMD's price to earnings (P/E) is 36% lower than its 5-year quarterly average of 63.6 but 16% higher than its last 4 quarters average of 35.1
Iradimed's quick ratio has decreased by 11% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of IRMD
Market
Valuations
Earnings
Shares outstanding
12.72M
Market cap
$841.68M
Enterprise value
$788.69M
Price to earnings (P/E)
40.6
Price to book (P/B)
8.92
Price to sales (P/S)
10.84
EV/EBIT
30.29
EV/EBITDA
29.4
EV/Sales
10.16
Revenue
$77.64M
Gross profit
$59.75M
Operating income
$23.81M
Net income
$20.66M
EBIT
$26.04M
EBITDA
$26.83M
Free cash flow
$13.33M
Per share
Balance sheet
Liquidity
EPS
$1.63
EPS diluted
$1.62
Free cash flow per share
$1.05
Book value per share
$7.42
Revenue per share
$6.11
TBVPS
$8.11
Total assets
$106.45M
Total liabilities
$12.15M
Debt
$0
Equity
$94.3M
Working capital
$68.56M
Debt to equity
0
Current ratio
8.78
Quick ratio
7.25
Net debt/EBITDA
-1.98
Margins
Efficiency
Dividend
EBITDA margin
34.6%
Gross margin
77%
Net margin
26.6%
Operating margin
30.7%
Return on assets
20.6%
Return on equity
23.3%
Return on invested capital
70.6%
Return on capital employed
26.7%
Return on sales
33.5%
Dividend yield
0.97%
DPS
$0.64
Payout ratio
40.8%
IRMD stock price
How has the Iradimed stock price performed over time
Intraday
13.42%
1 week
17.49%
1 month
9.35%
1 year
43.38%
YTD
20.31%
QTD
10.67%
Financial performance
How have Iradimed's revenue and profit performed over time
Revenue
$77.64M
Gross profit
$59.75M
Operating income
$23.81M
Net income
$20.66M
Gross margin
77%
Net margin
26.6%
The company's revenue rose by 12% YoY and by 3.3% QoQ
The company's operating income rose by 11% YoY and by 5% QoQ
Iradimed's net income has increased by 11% YoY and by 4.4% from the previous quarter
The gross profit is up by 11% YoY and by 3.4% QoQ
Price vs fundamentals
How does IRMD's price correlate with its fundamentals
Growth
What is Iradimed's growth rate over time
Valuation
What is Iradimed stock price valuation
P/E
40.6
P/B
8.92
P/S
10.84
EV/EBIT
30.29
EV/EBITDA
29.4
EV/Sales
10.16
IRMD's price to earnings (P/E) is 36% lower than its 5-year quarterly average of 63.6 but 16% higher than its last 4 quarters average of 35.1
Iradimed's EPS has increased by 10% YoY and by 3.8% QoQ
The price to book (P/B) is 31% higher than the 5-year quarterly average of 6.8 and 14% higher than the last 4 quarters average of 7.8
Iradimed's equity has increased by 18% YoY and by 4.7% QoQ
The price to sales (P/S) is 17% higher than the 5-year quarterly average of 9.3 and 17% higher than the last 4 quarters average of 9.3
The company's revenue rose by 12% YoY and by 3.3% QoQ
Efficiency
How efficient is Iradimed business performance
Iradimed's return on invested capital has decreased by 7% YoY and by 2.6% QoQ
Iradimed's return on equity has decreased by 6% YoY
Dividends
What is IRMD's dividend history
DPS
$0.64
Dividend yield
0.97%
Payout ratio
40.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Iradimed financials performed over time
Iradimed's total liabilities has increased by 18% YoY and by 4% QoQ
Iradimed's total assets has increased by 18% YoY and by 4.6% from the previous quarter
The company's debt is 100% lower than its equity
The company's debt has shrunk by 100% QoQ and by 100% YoY
Iradimed's equity has increased by 18% YoY and by 4.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.